The leading US health insurance trade group has hit out at the extremely high cost of new specialty medicines, accusing drug makers of taking advantage of the insurance system by pricing products at unsustainable levels. The latest salvo in the war on escalating US healthcare costs came from [b]AHIP – America's Health Insurance Plans[/b] – and targeted [b]Sovaldi[/b], the new $84,000 hepatitis C treatment from [b]Gilead Sciences[/b].
[link url=http://www.reuters.com/article/2014/05/20/us-insurance-gilead-sciences-drugcosts-idUSKBN0E029U20140520]– Reuters Health[/link]